LCAR-F33S for Relapsed/Refractory Multiple Myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a new CAR-T cell therapy called LCAR-F33S for people with multiple myeloma that has returned or stopped responding to standard treatments. It aims to see if targeting a specific protein on myeloma cells can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with multiple myeloma that has come back or not responded to treatment.
- You have already tried at least one proteasome inhibitor (e.g., bortezomib), one IMiD (e.g., lenalidomide), and one CD38 antibody (e.g., daratumumab).
- You have received at least three different lines of therapy for multiple myeloma.
- Your doctor expects you to live at least 3 more months.
- You do not have certain other blood disorders like plasma cell leukemia or amyloidosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment where your own immune cells (T cells) are collected, modified to find and attack myeloma cells, and given back to you. It is for people with multiple myeloma that has come back or not responded to several standard treatments.
This trial tests a new CAR-T cell therapy (a type of immune cell treatment) for people with multiple myeloma that has come back or not responded to several prior treatments. It aims to see if this therapy can help control the disease.
This trial tests a new CAR-T cell therapy called GC012F for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this treatment can help control the disease.
This Phase 1/2 study tests C-CAR088, a lab-made immune therapy, in people with multiple myeloma that has come back or did not respond. It is for patients who have already had several standard treatments and whose disease is still measurable.
This trial tests a new treatment using your own immune cells (called CAR-T cells) to fight multiple myeloma that has returned or not responded to earlier treatments. The treatment is designed to target and kill myeloma cells more effectively.
This trial tests a new type of immunotherapy called CAR T-cell therapy for people with multiple myeloma that has returned or not responded to standard treatments. The therapy uses your own immune cells, modified to attack the cancer, which may help you achieve a remission.
Hear when a new Relapsed/Refractory Multiple Myeloma (MM) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.